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    BRIEF COMMUNICATION   
Plasmid pGEN206 is a modiﬁ  ed form of 
pGEN222 (  17  ), in which we exchanged the 
  parA   locus with the   parM   and   parR   loci and 
introduced a   repA   locus between the multi-
ple cloning sites and the origin of replica-
tion. Cell-containing pellets and cleared 
culture supernatants were tested for CD8  –
  FasL fusion protein by immunoblotting 
using anti-FasL antibody as described (14). 
These results demonstrated the presence of 
CD8  –  FasL in both the bacterial cells and 
the culture supernatant (  Figure 1, A  ).         
  Attenuated   S. typhimurium   preferentially 
accumulate in tumors (  1    –    3  ,  19  ). To test the in 
vivo antitumor activity of FasL-expressing   S. 
typhimurium  , we used mouse cancer models 
in which mice were either injected subcuta-
neously with murine D2F2 breast carcinoma 
cells (n = 8 mice per group) or murine CT-
26 colon carcinoma cells (n = 5 mice per 
group) to form primary tumors or injected 
intravenously with D2F2 cells to form lung 
metastases (n = 8 mice per group). All animal 
experiments were performed according to 
the National Institutes of Health Guide for 
Care and Use of Experimental Animals and 
approved by the Animal Care Committee of 
the Burnham Institute for Medical Research 
(#AUF 04-152). Tumor-bearing mice were 
treated intravenously with phosphate-
  buffered saline (PBS), with   S. typhimurium,   
or with   S. typhimurium     containing control 
(empty) plasmid or FasL-encoding plasmid. 
In experiments involving subcutaneous 
tumors, mice were treated after tumors 
reached a size that was clearly visible, whereas 
for metastatic tumors, mice were treated at 6, 
13, and 20 days after the cancer cells were 
injected. Tumor volume was assessed with 
                  Attenuated   Salmonella typhimurium   have an 
excellent safety profile (  1  ,  2  ), a propensity to 
home to tumors (  3  ), and a capacity to syn-
thesize large quantities of functional human 
cytokines (  4  ). Our goal was to capitalize on 
these properties as a strategy for enhancing 
the tumoricidal activity of this strain. In this 
report, we performed a preclinical evalua-
tion of   S. typhimurium   bacteria engineered 
to produce the cytokine Fas ligand (FasL), 
also known as CD95L/APO-1L, using 
mouse tumor models. Our strategy was to 
engineer attenuated   S. typhimurium   to pro-
duce cytokines that have known antitumor 
activity but that are too toxic to use sys-
temically without targeting. 
  FasL is a membrane protein that belongs 
to the tumor necrosis factor family of pro-
teins. After binding to its receptor (Fas), it 
initiates an apoptotic signal in Fas-sensitive 
cells (  5  ). This mechanism is of particular 
importance for a variety of physiological and 
pathological conditions, including the killing 
of transformed target cells by cytotoxic T 
lymphocytes and natural killer cells (  6  ). In 
addition to its proapoptotic activity, however, 
many other potentially useful functions have 
been described for FasL [reviewed in (  7  )], 
including chemotactic properties toward 
granulocytes (  8  ,  9  ) that promote tumor rejec-
tion (  9  ), induction of IL-23 production by 
dendritic cells (  10  ), and stimulation of CD8        
T-cell proliferation (  11  ). However, systemic 
administration of recombinant FasL or of 
agonistic anti-Fas antibodies has been shown 
to induce lethal liver injury (  12  ,  13  ), making 
untargeted systemic delivery an unacceptable 
strategy. Here, we used FasL as a test case for 
investigating the feasibility of using attenu-
ated   S. typhimurium   as a tumor-  speciﬁ  c trans-
porter for cytotoxic and immunostimulatory 
therapeutic proteins. 
  To engineer the attenuated   S. typhi-
murium   strain   purI0-/msbB-   (  14  ) to express 
FasL, we transformed these bacteria with 
the plasmid pGEN206, from which a fusion 
of the extracellular domains of human CD8    
and murine FasL [FasL  –  CD8, a gift from 
Dr H. Yigaki (15)] with an appended N-
terminal leader sequence that directs pro-
tein secretion [MISSSSIS ( 16  )] was expressed 
under the control of an   ompC   promoter. 
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    Intravenous administration of bacteria leads to their accumulation in tumors and to 
sporadic tumor regression. We therefore explored the hypothesis that   Salmonella 
typhimurium   engineered to express the proapoptotic cytokine Fas ligand (FasL) 
would exhibit enhanced antitumor activity. Immunocompetent mice carrying tumors 
derived from syngeneic murine D2F2 breast carcinoma or CT-26 colon carcinoma 
cells were treated intravenously with FasL-expressing   S. typhimurium   or with 
  phosphate-buffered saline (PBS; control). Treatment with FasL-expressing   S. 
typhimurium   inhibited growth of primary tumors by an average of 59% for D2F2 
tumors and 82% for CT-26 tumors (eg, at 25 days after initial treatment, mean 
volume of PBS-treated CT-26 colon carcinomas = 1385 mm 
3   and of   S. typhimurium   
FasL-treated CT-26 tumors = 243 mm 
3  , difference = 1142 mm  3  , 95% confidence 
  interval = 800 mm 
3   to 1484 mm  3  ,   P   < .001). Pulmonary D2F2 metastases (as measured 
by lung weight) were reduced by 34% in   S. typhimurium   FasL-treated mice com-
pared with PBS-treated mice. FasL-expressing   S. typhimurium   had similar effects on 
growth of murine B16 melanoma tumors in wild-type mice but not in   lpr/lpr   mice, 
which lack Fas, or in mice with disrupted host inflammatory responses. Antitumor 
activity was achieved without overt toxicity. These preclinical results raise the possi-
bility that using attenuated   S. typhimurium   to deliver FasL to tumors may be an 
effective and well-tolerated therapeutic strategy for some cancers. 
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nal work is properly cited.   calipers every 4 days from days 14 to 46 for 
D2F2 breast tumors (  Figure 1, B  ) and on 
days 11, 16, 21, and 25 for CT-26 colon 
tumors (  Figure 1, C  ).
In mice treated with   S. typhimurium   con-
taining the FasL expression vector, tumor 
growth was statistically signiﬁ  cantly reduced 
compared with that in control groups. For 
example, after 46 days of treatment, mean 
D2F2 tumor volumes were 827, 847, 949, 
and 336 mm  3   for the groups treated with 
PBS,   S. typhimurium  ,   S. typhimurium  –vector, 
and   S. typhimurium  –FasL, respectively (for 
PBS- vs FasL-treated D2F2 tumors, differ-
ence = 491 mm  3  , 95% conﬁ  dence interval 
[CI] = 34 to 984,   P   = .02) (  Figure 1, B  ). At 
25 days after initial treatment, mean CT-26 
tumor volumes were 1385 mm  3   and 243 
mm  3   for the groups treated with PBS vs   S. 
typhimurium  –FasL, respectively (difference 
= 1142 mm  3  , 95% CI = 800 to 1484,   P   < 
.001) (  Figure 1, C  ). We also observed that 
mice treated with FasL-expressing   S. typh-
imurium   showed a 34% reduction in the 
    CONTEXT AND CAVEATS 
    Prior knowledge 
    Salmonella typhimurium  , a facultative an  -
aerobe, has been shown to accumulate at 
tumor sites when injected intravenously 
into mouse tumor models. Intravenous 
injec      tion of attenuated strains has been 
well tolerated.   
    Study design 
  Attenuated   S. typhimurium   were engi-
neered to express Fas ligand (FasL) to 
deliver this toxic, antitumor cytokine to 
tumor sites and to thereby enhance thera-
peutic potential.   
    Contribution 
    S. typhimurium   expressing FasL dramati-
cally inhibited the growth of D2F2 murine 
breast carcinoma and CT-26 murine colon 
carcinoma tumors, as well as the growth of 
D2F2 pulmonary metastases in mice.   
    Implications 
    S. typhimurium   expressing FasL may hold 
promise for the treatment of some human 
tumors.   
    Limitations 
  These experiments involved murine tumor 
models, and the effects of FasL-expressing 
  S. typhimurium   on human tumor models 
are not yet known. 
    From the Editors           
   
  Figure 1    .       Inhibition of tumor growth using Fas ligand (FasL)  –  expressing   Salmonella typhimurium  . 
  A  ) FasL expression and secretion. FasL protein expression was veriﬁ  ed by immunoblot analysis 
of cell lysates (pellet) or culture supernatants (sup) from   S. typhimurium   containing empty vec-
tor (Sal) or FasL-expressing plasmid–transformed   S. typhimurium   (Sal + FasL). Immunoblots 
were performed as described previously (  14  ). Samples were normalized for total protein content. 
Blots were probed with rat monoclonal anti-mouse FasL antibody (Alexis, San Diego, CA) at 
1:500 dilution. Protein  –  antibody complexes were visualized by an enhanced chemiluminescence 
(ECL) method (Amersham). Results are representative of three independent experiments. 
  B  ) Effect on D2F2 tumor growth. BALB/c mice (n = 8 per group) were subject to subcutaneous 
injection with 1.5 × 10  5   D2F2 breast carcinoma cells suspended in 100   µ  L of phosphate-buffered 
saline (PBS) followed after 14 days by intravenous treatment with PBS (  closed diamonds  ),   S. 
typhimurium   (  closed squares  ),   S. typhimurium   with empty vector (  closed triangles  ), or 
  S. typhimurium   with FasL vector (  open circles  ). All bacterial doses were 5 × 10  6   colony-forming 
units per mouse suspended in 100   µ  L of PBS, a dose selected based on prior preclinical and clini-
cal studies and that is known to be nontoxic or minimally toxic (1,3,16). All graphs indicate aver-
age tumor volumes as estimated by external calipers (means with 95% conﬁ  dence intervals 
[CIs]) (  14  ). Results are representative of four independent experiments.   C  ) Effect on CT-26 tumor 
growth. BALB/c mice (n = 5 per group) were injected subcutaneously with 2.5 × 10  5   CT-26 colon 
carcinoma cells followed 9, 14, and 19 days later by intravenous treatment with PBS (  closed dia-
monds  ) or   S. typhimurium   with FasL vector (  open circles  ). Graphs indicate average tumor vol-
umes from the time that tumor challenge was initiated (means with 95% CIs). Results are 
representative of four independent experiments.   D  ) and   E  ) Effect on D2F2 metastasis. BALB/c 
mice (n = 8 per group) were injected intravenously with 7.5 × 10  4   D2F2 breast carcinoma cells 
followed 6, 13, and 20 days later by intravenous treatment with PBS,   S. typhimurium   (Sal),   S. 
typhimurium   containing empty vector (Sal + vector), or   S. typhimurium   containing the FasL 
plasmid (Sal + FasL). Mice were killed after 41 days with an overdose of intraperitoneal Avertin 
anesthetic (0.017 mL/g body weight; Aldrich, Milwaukee, WI) followed by cervical dislocation. 
and lungs were weighed (  D  ) and examined for metastases (  E  ). The fraction of lung surface cov-
ered by fused metastases was scored as follows: 0 = 0%, 1 = less than 20%, 2 = 20%  –  50%, 3 = 
more than 50%. Values are means with 95% CIs. *  P   < .05. Results are representative of four 
independent experiments. D2F2 cells were a gift from Dr Wei-Zen Wei (Karmanos Cancer 
Institute, Detroit, MI) and CT-26 cells were obtained from ATCC (Manassas, VA). Female BALB/c 
mice at 6  –  8 weeks of age were purchased from The Jackson Laboratory (Bar Harbor, ME). Two-
tailed Student   t   tests were used to determine the statistical signiﬁ  cance of primary tumor growth 
differences between control and treatment groups. In the case of metastasis scores, statistical 
signiﬁ  cance was determined by Mann  –  Whitney   U   tests.   P   values of .05 or less were deemed sta-
tistically signiﬁ  cant.       
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(as measured by lung weight) compared 
with PBS -treated control mice, with lung 
weights remaining almost normal compared 
with mice receiving other treatments (mea-
sured at 41 days, mean lung weights were 
0.29 g, 0.27 g, 0.34 g, and 0.19 g for the PBS, 
  S. typhimurium  ,   S. typhimurium  – vector, and 
  S. typhimurium  –FasL groups, respectively; 
for PBS- vs FasL-treated D2F2 metastases, 
difference = 0.10 g, 95% CI = 0.04 to 0.16, 
  P   = .001) (  Figure 1, D and E  ). 
  To investigate the dependence of the 
antitumor effect on the expression of 
endogenous Fas in the host, we implanted 
B16 mouse melanoma cells into C57/B16 
mice with wild-type or   lpr/lpr   backgrounds. 
FasL-expressing   S. typhimurium   failed to 
inhibit B16 tumor growth in   lpr/lpr  -mice, 
which lack Fas, in contrast to wild-type 
control mice. Mean tumor volumes were 
1882 mm  3   for PBS (control)-treated wild-
type mice vs 1761 mm  3   for   S. typhimurium  –
FasL-treated   lpr/lpr   mice (difference = 121 
mm 
3  , 95% CI =     811 mm 
3   to 1053 mm 
3  ,   P   = 
.73) at 22 days after treatment (  Figure 2, 
B  ). Thus, the antitumor activity of FasL-
expressing   S. typhimurium    depends at least 
in part on expression of intact Fas on host 
cells rather than tumor cells.         
  It has been previously demonstrated 
that FasL is chemotactic for neutrophils, 
and this activity can be indispensable for 
efﬁ  cient inhibition of tumor growth under 
some circumstances (  9  ). In this regard, we 
observed an increase in inﬂ  ammatory 
cells, particularly neutrophils, within sub-
cutaneously grown D2F2 breast tumors 
in mice treated with FasL-expressing   
S. typhimurium  , as determined by hematox-
ylin and eosin staining and by immunohis-
tochemistry using anti  –  Ly-6G staining 
(  Figure 2, A   and Supplementary Figure, 
available online). To experimentally investi-
gate the role of neutrophils in the antitumor 
activity of FasL-expressing   S. typhimurium  , 
we depleted neutrophils in vivo using an 
anti  –  Ly-6G antibody (  20  ) before beginning 
treatment of B16 melanoma  –  bearing mice 
with FasL-expressing   S. typhimurium   
(  Figure 2, B  ). Tumor weights from killed 
mice showed that the antitumor effects of 
targeted FasL were abolished when neutro-
phils were depleted (mean tumor weight for 
mice treated with   S. typhimurium  –FasL + 
anti  –  Ly-6G = 1405 mg, tumor weight for 
mice treated with   S. typhimurium  –FasL in 
   
  Figure 2    .       Roles of neutrophils and Fas in observed antitumor effects.   A  ) Accumulation of neutro-
phils in Fas ligand (FasL)  –  treated D2F2 breast tumors. Treated and untreated mice were killed 
with an overdose of intraperitoneal Avertin anesthetic (0.017 mL/g body weight; Aldrich, 
Milwaukee, WI) followed by cervical dislocation. Tumor tissues from BALB/c mice (n = 3 per 
group) were ﬁ  xed in paraformaldehyde, embedded in parafﬁ  n, and subjected to histopathologic 
analyses using staining with hematoxylin and eosin and with an antibody speciﬁ  c for the Ly-6G 
antigen (BD, Franklin Lakes, NJ). Shown are high-power ﬁ  eld examples (×400 magniﬁ  cation) of 
D2F2 breast tumors from mice treated intravenously with phosphate-buffered saline (PBS), 
  S. typhimurium   (Sal),   S. typhimurium   plus empty vector (Sal + vector), or   S. typhimurium   plus 
FasL-bearing vector (Sal + FasL).   B  ) Dependence of treatment on host neutrophils and Fas. C57/
Bl6 mice (n = 5 per group) were injected subcutaneously with 10 
5   B16 murine melanoma cells. 
After 7 days, mice were injected intravenously with PBS,   S. typhimurium   (Sal),   S. typhimurium   
plus empty vector (Sal + vector), or   S. typhimurium   plus FasL-bearing vector (Sal + FasL). Test 
groups also included mice treated with Sal + FasL 5 and 15 days after intraperitoneal treatment 
with 500   µ  g per mouse of Ly-6G antibody, an antibody that depletes neutrophils (Sal + FasL + 
anti  –  Ly-6G), and C57/Bl6 mice lacking Fas (Sal + FasL in   lpr   mice). Mice were killed after 22 days, 
and tumor weights were determined (means with 95% conﬁ  dence intervals). *  P   < .05. Results are 
representative of three independent experiments. B16 cells were obtained from ATCC (Manassas, 
VA). Female C57/Bl6 and   lpr/lpr   mice (6  –  8 weeks of age) were supplied by The Jackson 
Laboratory (Bar Harbor, ME).       
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which neutrophils were not depleted = 
679 mg, difference = 726 mg, 95% CI = 
355 to 1097 mg,   P   = .001). 
  Although demonstrating antitumor 
activity, FasL-expressing   S. typhimurium   
did not cause greater systemic toxicity than 
the unmodiﬁ  ed attenuated   S. typhimurium   
strain. Histological analysis of multiple 
organs (lungs, kidneys, spleens, and heart) 
showed minimal changes (data not shown) 
that were comparable to the results obtained 
previously with control   S. typhimurium   that 
did not produce FasL (  7    –    10  ). Thus, addi-
tion of FasL did not worsen the toxicity 
observed with   S. typhimurium  , which has 
been shown previously to be well tolerated 
in humans (  1  ,  4  ). 
  Here, we have demonstrated that sys-
temic delivery of attenuated  S. typhimurium   
expressing a soluble version of FasL 
reduces growth of primary tumors and 
pulmonary metastases in mouse cancer 
models (  21  ) using multidrug-resistant 
murine tumors in immunocompetent ani-
mals. In mice depleted in vivo of neutro-
phils, the antitumor effect of treatment 
with FasL-expressing bacteria was severely 
impaired, corroborating ﬁ  ndings  from 
previous studies in which FasL was applied 
intratumorally (  9  ). Moreover, Fas expres-
sion on host rather than tumor cells was 
found to be critical for antitumor activity, 
based on experiments using   lpr/lpr   mice, 
which lack the receptor for FasL. Thus, 
the observed antitumor effects of FasL-
expressing   S. typhimurium   appear to rely 
largely on a host inﬂ  ammatory reaction to 
the tumor, rather than on a direct pro-
apoptotic effect on tumor cells. 
  Unlike systemically delivered agonistic 
anti-Fas antibodies or FasL, which have 
toxic effects, mice appeared to tolerate 
FasL-expressing bacterial therapy well; 
however, formal preclinical toxicology 
studies should be performed. Histopathologic 
analyses of various organs showed only 
modest changes that were similar in extent 
for control and FasL-expressing   S. 
typhimurium  , thus conﬁ  rming  previous 
reports (  2  ,  19  ). Together with other pre-
clinical (  1  ,  19  ) and clinical (  22  ) studies that 
have documented minimal side effects of 
intravenous administration of attenuated   S. 
typhimurium  , these results from murine 
cancer models suggest that FasL-  expressing 
  S. typhimurium   could offer an acceptable 
strategy for employing FasL and possibly 
other toxic cytokines for cancer therapy.       
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